3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
7
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Breast Neoplasms
3
Leukoplakia, Oral
2
Erythroplasia
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms by Site
1
Mouth Neoplasms
1
Metabolic Diseases
1
Melanoma
1
Medulloblastoma
1
Insulin Resistance
1
Infertility
1
Hyperplasia
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Drug-drug Interaction,SHR3680
1
Interventions
pembrolizumab
12
Cisplatin
11
Specimen Handling
9
Bevacizumab
7
Brachytherapy
6
Platinum
5
Paclitaxel
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Human Papillomavirus DNA Tests
5
Colposcopy
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Fulvestrant
4
Surveys and Questionnaires
3
Radiotherapy
3
Radiation Dose Hypofractionation
3
Radiation
3
Drug Therapy
3
Blood Specimen Collection
3
1,2-diaminocyclohexaneplatinum II citrate
3
tisotumab vedotin
2
palbociclib
2
lenvatinib
2
Topotecan
2
Restraint, Physical
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Metformin
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled